Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Accenture plc (ACN) vs Novavax Inc (NVAX) Price & Performance

Accenture plcTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Accenture plc vs Novavax Inc — how do they compare? Accenture plc trades at $179.65 (market cap $110.04B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Accenture plc is far larger — about 84× Novavax Inc's market cap, and Accenture plc pays a 3.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

ACNNVAX
Market Cap
$110.04B$1.31B
Sector
TechnologyHealth
52-Week High
$288.54$11.19
52-Week Low
$124.41$6.22
Enterprise Value
$108.26B$889.30M
Dividend Yield
3.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Accenture plc

Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.

Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Accenture plc

Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.

Read more on ACN

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX